Novartis, a global leader in pharmaceuticals, has made substantial commitments to ESG principles, particularly in healthcare accessibility and sustainability. The company has set ambitious goals to reduce its carbon emissions and achieve net-zero emissions by 2030, alongside efforts to ensure affordable healthcare for underserved communities. Novartis’ ESG rating highlights its contributions to innovative treatments and global health. However, the company faces criticism regarding drug pricing and its historical ties to controversies over opioid distribution in some markets. Novartis' ESG score reflects a strong focus on environmental and social responsibility, but it must address governance and pricing concerns to further enhance its credibility. The latest Novartis ESG report provides insights into the company’s sustainability and social impact efforts.